The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naive RET-driven cancer models.

Drilon, AE; Zhai, DY; Rogers, E; Deng, W; Zhang, X; Ung, J; Lee, D; Rodon, L; Graber, A; Zimmerman, ZF; Murray, BW; Subbiah, V

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索